SPRO vs. DRUG

Last updated Jun 23, 2026

SPRO (Spero Therapeutics, Inc.) and DRUG (Bright Minds Biosciences Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, SPRO returned -31.31%/yr vs 22.44%/yr for DRUG. At a 0.10 correlation, their price movements are largely independent.

Performance

SPRO vs. DRUG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Spero Therapeutics, Inc. (SPRO) and Bright Minds Biosciences Inc (DRUG). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, SPRO achieves a -5.15% return, which is significantly higher than DRUG's -18.64% return.

SPRO

• 1D: -3.07%
• 1M: -19.93%
• YTD: -5.15%
• 6M: -6.75%
• 1Y: -26.82%
• 3Y*: 11.37%
• 5Y*: -31.31%
• 10Y*: —

DRUG

• 1D: 4.67%
• 1M: -23.96%
• YTD: -18.64%
• 6M: -23.52%
• 1Y: 132.48%
• 3Y*: 178.18%
• 5Y*: 22.44%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

SPRO vs. DRUG - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
SPRO Spero Therapeutics, Inc.	-5.15%	126.21%	-29.93%	-15.03%	-89.19%	0.88%
DRUG Bright Minds Biosciences Inc	-18.64%	116.66%	2,418.88%	-61.35%	-76.66%	-39.45%

Correlation

The correlation between SPRO and DRUG is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.20
Correlation (3Y) Calculated over the trailing 3-year period	0.13
Correlation (5Y) Calculated over the trailing 5-year period	0.10
Correlation (All Time) Calculated using the full available price history since Mar 22, 2021	0.10

Fundamentals

Market Cap SPRO : $126.59M DRUG : $608.86M
EPS SPRO : $0.39 DRUG : -CA$3.48
PB Ratio SPRO : 2.39 DRUG : 2.80
Total Revenue (TTM) SPRO : $54.77M DRUG : CA$0.00
Gross Profit (TTM) SPRO : $54.51M DRUG : -CA$20.13K
EBITDA (TTM) SPRO : $12.49M DRUG : -CA$31.36M

Return for Risk

SPRO vs. DRUG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SPRO

SPRO Risk / Return Rank: 20
SPRO Sharpe Ratio Rank: 22
SPRO Sortino Ratio Rank: 25
SPRO Omega Ratio Rank: 24
SPRO Calmar Ratio Rank: 17
SPRO Martin Ratio Rank: 16

DRUG

DRUG Risk / Return Rank: 85
DRUG Sharpe Ratio Rank: 87
DRUG Sortino Ratio Rank: 85
DRUG Omega Ratio Rank: 80
DRUG Calmar Ratio Rank: 86
DRUG Martin Ratio Rank: 86

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SPRO vs. DRUG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Spero Therapeutics, Inc. (SPRO) and Bright Minds Biosciences Inc (DRUG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	SPRO	DRUG	Difference
Sharpe ratio: Return per unit of total volatility	-0.46	1.82	-2.28
Sortino ratio: Return per unit of downside risk	-0.30	2.59	-2.89
Omega ratio: Gain probability vs. loss probability	0.96	1.29	-0.33
Calmar ratio: Return relative to maximum drawdown	-0.68	3.47	-4.15
Martin ratio: Return relative to average drawdown	-1.16	9.08	-10.25

SPRO vs. DRUG - Sharpe Ratio Comparison

The current SPRO Sharpe Ratio is -0.46, which is lower than the DRUG Sharpe Ratio of 1.82. The chart below compares the historical Sharpe Ratios of SPRO and DRUG, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

SPRO vs. DRUG - Drawdown Comparison

The maximum SPRO drawdown since its inception was -97.46%, roughly equal to the maximum DRUG drawdown of -97.68%. Use the drawdown chart below to compare losses from any high point for SPRO and DRUG.

Drawdown Indicators

	SPRO	DRUG	Difference
Max Drawdown Largest peak-to-trough decline	-97.46%	-97.68%	+0.22%
Max Drawdown (1Y) Largest decline over 1 year	-39.80%	-38.35%	-1.45%
Max Drawdown (3Y) Largest decline over 3 years	-68.89%	-76.98%	+8.09%
Max Drawdown (5Y) Largest decline over 5 years	-97.13%	-97.68%	+0.55%
Current Drawdown Current decline from peak	-89.99%	-33.85%	-56.14%
Average Drawdown Average peak-to-trough decline	-62.42%	-58.76%	-3.66%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.07%	14.64%	+8.43%

Volatility

SPRO vs. DRUG - Volatility Comparison

Spero Therapeutics, Inc. (SPRO) has a higher volatility of 33.20% compared to Bright Minds Biosciences Inc (DRUG) at 18.60%. This indicates that SPRO's price experiences larger fluctuations and is considered to be riskier than DRUG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SPRO	DRUG	Difference
Volatility (1M) Calculated over the trailing 1-month period	33.20%	18.60%	+14.60%
Volatility (6M) Calculated over the trailing 6-month period	45.15%	44.58%	+0.57%
Volatility (1Y) Calculated over the trailing 1-year period	58.66%	73.50%	-14.84%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	152.13%	662.99%	-510.86%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	124.91%	646.62%	-521.71%

Dividends

SPRO vs. DRUG - Dividend Comparison

Neither SPRO nor DRUG has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both SPRO and DRUG in my portfolio?

SPRO and DRUG have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, SPRO or DRUG?

SPRO has higher volatility (33.20%) compared to DRUG (18.60%). In terms of maximum drawdown, SPRO dropped -97.46% vs DRUG's -97.68%.

Which has better risk-adjusted returns?

DRUG currently has the higher Sharpe Ratio (1.82 vs -0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.